Consumer bodies urge EMA to "go further" on trial data disclosure
This article was originally published in Scrip
Executive Summary
Consumer and activist groups have welcomed the European Medicines Agency's draft policy on proactive disclosure of clinical trial data, but have urged it to go further and apply the policy to trials of drugs already on the market, rather than just those submitted for approval from January next year.